Both in Pharmaceuticals
Fulcrum Therapeutics vs Emergent Biosolutions
Over the past year FULC returned −55.0% and EBS returned −41.5%; their daily moves had a correlation of 0.10.
FULC −55.0% EBS −41.5%Growth of $1, one year, split-adjusted
| Metric | FULC | EBS |
|---|---|---|
| Price | $3.77 | $5.90 |
| Market cap | $288.0M | $302.5M |
| Today | +0.80% | −5.60% |
| 1 month | +2.2% | −15.1% |
| 6 months | −47.0% | −35.2% |
| Year to date | −66.7% | −52.3% |
| 1 year | −58.2% | −43.8% |
| Revenue growth (YoY) | — | −52.4% |
| Gross margin | — | 26.5% |
| Net margin | — | −29.7% |
| P/E (TTM) | — | — |
| Price / sales | — | 0.5× |
| Net cash | $318.8M | -$332.0M |
| Dividend yield | — | — |
| Volatility (60d) | 15.0% | 64.9% |
| Short % of float | 10.6% | 19.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).